NYU Winthrop and Progenity Collaborate to Develop Diagnostic Test to Assess Risk for Preterm Birth

Announcing a collaborative research and development initiative for women’s health with a focus on preterm births.

Mineola, NY and San Diego, CA – NYU Winthrop Hospital and Progenity, Inc., today announced a collaborative research and development initiative for women’s health with a focus on preterm births. As part of the initiative, NYU Winthrop granted Progenity an exclusive license to key intellectual property for which NYU Winthrop holds patents in the U.S. and Europe (see US Patent No. 9,797,903 and European Patent No. EP2912458). The granted patents are directed to a biomarker for predicting preterm births, and the two organizations are collaborating on discovery studies to identify additional preterm birth markers, as well as the clinical validation of other reproductive health tests for Progenity. NYU Winthrop is the Long Island affiliate of NYU Langone Health.

View the full release here.

Support